Clinical trial
Clinical Value of EMR3 in Early Diagnosis, Dynamic Monitoring, and Prognostic Assessment of Sepsis: A Multicenter Prospective Observational Study in China
NCT07896018 is registered in ClinicalTrials.gov with Sir Run Run Shaw Hospital as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Recruiting, started November 2026. Observational study, 3,000 participants (estimated). Lead sponsor Sir Run Run Shaw Hospital; China. Primary measure: Diagnostic Accuracy of Neutrophil EMR3 Expression for Sepsis. 7 linked papers (newest 2023).
How it compares
415 similar trials: same condition (Shock, Septic) and phase
Registry record
As filed in ClinicalTrials.gov.
- Title
- Clinical Value of EMR3 in Early Diagnosis, Dynamic Monitoring, and Prognostic Assessment of Sepsis: A Multicenter Prospective Observational Study in China
- Lead sponsor
- Sir Run Run Shaw Hospital
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- November 30, 2026
- Completion date
- September 30, 2027
- Enrollment
- 3,000 (estimated)
- Sites
- 1
Conditions
MeSH condition names; the registry's own terms follow.
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Minimum age
- 18 Years
- Healthy volunteers
- Yes
- Study type
- Observational
- Sites
- 1
- Countries
- China
- Lead sponsor
- Sir Run Run Shaw Hospital
Arms
As registered; 4 arms.
| Arm | Type | Interventions |
|---|---|---|
| Sepsis/Septic Shock | ||
Show registry wordingPatients aged 18 years or older diagnosed with sepsis or septic shock according to the Sepsis-3 criteria. Neutrophil EMR3 expression will be assessed at baseline, 72 ± 12 hours, and day 7 ± 1 day, with an optional measurement at day 14 ± 2 days, using residual blood samples from routine clinical care. Clinical outcomes will be followed for 28 days. | ||
| Infection Without Sepsis | ||
Show registry wordingAdult patients with confirmed or suspected infection who do not meet the Sepsis-3 diagnostic criteria for sepsis. Neutrophil EMR3 expression will be measured at baseline using residual blood samples from routine clinical care. This group will serve as a comparator for evaluating the diagnostic accuracy of EMR3 in identifying sepsis. | ||
| Noninfectious Critical Illness | ||
Show registry wordingAdult critically ill patients with noninfectious conditions, such as trauma, postoperative inflammation, acute pancreatitis, acute heart failure, or pulmonary embolism, without evidence of infection based on final clinical adjudication. Baseline neutrophil EMR3 expression will be measured to evaluate its diagnostic specificity in distinguishing sepsis from noninfectious critical illnesses. | ||
| Healthy or Elective Surgical Controls | ||
Show registry wordingHealthy adults undergoing routine health examinations or patients undergoing elective surgery who meet the study eligibility criteria. Baseline neutrophil EMR3 expression will be measured using residual blood samples to establish reference expression levels and evaluate the stability of the flow cytometry assay. This group will not be included in the primary diagnostic comparison. | ||
Primary endpoints
Registered primary outcome measures; 1 primary.
| Measure | Time frame |
|---|---|
| Diagnostic Accuracy of Neutrophil EMR3 Expression for Sepsis | At baseline (T0), within 6 hours of enrollment or initial ICU admission. |
Show registry wordingThe diagnostic accuracy of baseline neutrophil EMR3 expression for identifying sepsis will be evaluated using the area under the receiver operating characteristic curve (ROC-AUC), with a 95% confidence interval. EMR3 expression will be measured by flow cytometry using residual EDTA-anticoagulated whole blood. The primary comparison will be between patients with sepsis or septic shock and patients with infection without sepsis or noninfectious critical illness. Healthy or elective surgical controls will be excluded from the primary diagnostic comparison. | |
Papers
PubMed papers this trial cites; 7 papers, results papers first, then newest first.
+2 more papers
Lead sponsor's other trials
Sir Run Run Shaw Hospital, most recent start first.
+129 more trials See the organization page
Similar trials
Same condition (Shock, Septic) and phase, most recent start first.
+410 more trials See the condition page